Clinical trial NCT04168580: Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
Official title: Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Metabolic Diseases
Lead sponsor: AdventHealth Translational Research Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2019-11-19
Enrollment: 30
Sex: ALL
Minimum age (years): 65
Maximum age (years): 90
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this study is to define the effect of aging on brown adipose tissue mass in a cohort of older sedentary and older athlete adults.

Detailed description: Brown adipose tissue is a thermogenic tissue that contains large capacity to dissipate energy as heat. When activated by either cold-stimulation or increasing the amount of brown adipose tissue by transplantation, brown adipose tissue increases energy expenditure, decreases plasma glucose and lipids and improves systemic metabolism.

Brown adipose tissue has great potential as a therapeutic target to combat both metabolic and cardiovascular disease, but brown adipose tissue decreases with age. The objective of this study is to define the effect of aging on brown adipose tissue mass in a cohort of older sedentary and older athlete adults. Studying the role of brown adipose tissue will potentially help us understand and prevent an accelerated aging process, which will help researchers better understand metabolic and cardiac health in the elderly.

Eligibility criteria: Inclusion Criteria:

1. Males and Females between the ages of 65 to 90 years of age.
2. BMI 35kg/m2, inclusive at time of screening.
3. Stable weight (No gain/loss of ≥ 10 lbs within 6 months prior to screening).
4. Non-smokers as defined by not smoking any tobacco or using nicotine-containing products and not using vape pens or vaporizers within 3 months prior to screening.
5. Participant must have renal function with an estimated glomerular filtration rate (eGFR) \> 45 ml/min/1.73m2 determined at screening.
6. Triglyceride level is \< 350 mg/dl and LDL cholesterol is ≤ 150 mg/dl at screening.
7. States willingness to follow protocol as described, including the prescribed exercise level and completing any forms needed throughout the study.
8. Voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

   Group Specific Inclusion Criteria:
9. Older Athletes (OA) Only: Endurance trained athletes, defined as exercising (running, cycling, swimming) \>3days/wk for \>6 months without layoff. This will be verified by self-report and triaxial accelerometry.
10. Older Sedentary (OS) Only: Defined as \<1day/wk of structured exercise and determined by self-report and triaxial accelerometry.

Exclusion Criteria:

1. History of type 1 or type 2 diabetes per self-report at screening visit 1.
2. Actively pursuing weight loss and/or lifestyle changes at time of screening.
3. Untreated or poorly controlled hypertension (Systolic \> 150, Diastolic \> 95).
4. Mini Mental State Exam (MMSE) \<21.
5. Participant has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained.
6. Current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit.
7. Participant is currently taking anti-inflammatory medication or has had anti-inflammatory medication within 1 week prior to screening (including over the counter formulations; e.g. Aleve, Motrin, ibuprofen, naproxen, low dose aspirin).
8. Surgery requiring \>2 days of hospitalization in the last 3 weeks prior to screening visit.
9. Participant has an active malignancy (with the exception of basal cell) or autoimmune disease.
10. Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV, per self-report.
11. Participant is an amputee and/or has presence of partial or full artificial limb.
12. Participant currently has uncontrolled severe diarrhea, nausea or vomiting.
13. Participant has uncontrolled severe (including stage III or above) gastrointestinal absorption-related disorders, within 3 months of screening, such as: obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome, gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery.
14. Cannot abstain from alcohol for the duration of the testing periods.
15. Subjects who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos.
16. Unable to participate in Magnetic Resonance or DEXA assessments due to physical limitations of equipment tolerances (e.g., MRI bore size and DEXA 450-pound weight limit), claustrophobia, or based on Investigator's judgment at screening.
17. Participant cannot refrain from taking medications/dietary supplements/herbals or substances that could modulate glucose metabolism, or are considered anabolic, or reduce weight (fat mass) in the opinion of the PI or Physician, starting two weeks prior to enrollment and over the entire course of the study. These include progestational agents, steroids, growth hormone, dronabinol, marijuana, calcium-betahydroxy-betamethylbutyrate (CaHMB), free amino acid supplements and dietary supplements to aid weight loss.
18. Participant has hypothyroidism (0.5mI U/L) or hyperthyroidism (10mI U/L).
19. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.
20. Because all women participating in this project will be post-menopausal, there will be no need for a pregnancy test prior to DEXA procedures. Females currently on hormone replacement therapy can participate in the study if they have been on a stable dose of Hormone Replacement Therapy (HRT) for at least 6 months and will continue to be on HRT during the study.
21. Potential participants taking stable doses of medications for the last 30 days prior to screening for Blood pressure, cholesterol, gastroesophageal reflux disease (GERD) may be permitted to participate.
22. Participant becomes Covid-19 positive at any point during the study.

Primary outcomes:
measure: Collection of imaging of BAT by magnetic resonance imaging
timeFrame: 30 minutes
Secondary outcomes:
measure: Aerobic fitness
timeFrame: 4 days per week, 30 minutes, 8 weeks
measure: Aerobic fitness
timeFrame: 4 days per week, 30 minutes, 8 weeks
measure: Muscle testing
timeFrame: 4 days per week, 30 minutes, 8 weeks
measure: Physical function (SPPB)
timeFrame: 4 days per week, 30 minutes, 8 weeks
measure: Aerobic fitness
timeFrame: 4 days per week, 30 minutes, 8 weeks
Other outcomes:
Locations:
city: Orlando
country: United States
facility: AdventHealth Translational Research Institute
state: Florida
Study officials:
affiliation: Study Principal Investigator
name: Paul Coen, PhD
role: PRINCIPAL_INVESTIGATOR
References: